Fair Lawn, NJ (April 12, 2004) - Lonza Ltd. filed suit in the District Court for the Southern District of New York against Nutraceutical International Corporation and several of its subsidiaries for infringement of Lonza Ltd.’s U.S. Patent No. 5,073,376. Nutraceutical markets products under the trademarks Kal, Nature’s Life, Solaray and Natural Max.
The subject patent covers enteric preparations of L-Carnitine L-Tartrate. The validity of all of the claims of the Lonza patent was recently confirmed during re-examination by the U.S. Patent and Trademark Office.
Lonza is a leader in the industry in promoting the nutritional uses of L-Carnitine, a nutrient beneficial for weight loss, athletic performance and general cardiovascular health. Lonza has devoted substantial ingenuity and resources to develop its pat-ent and trademark portfolio for the nutritional uses of L-Carnitine. This suit is the first action brought by Lonza Ltd. against a manufacturer of products containing unlicensed L-Carnitine L-Tartrate, and represents a major step in Lonza’s continu-ing efforts to maintain and enforce its patent rights in the L-Carnitine market.
Lonza is a life sciences driven company, headquartered in Switzerland, which gen-erated sales of CHF 2.24 billion in 2003. It operates 18 production and R&D facili-ties in eight countries and employs 5,660 people worldwide. Lonza is one of the leading custom manufacturers of chemical intermediates and active ingredients as well as biopharmaceuticals for the pharmaceutical and agrochemical industries. In addition, Lonza also offers organic intermediates for a wide range of applications and provides antimicrobial and associated products as well as polymer intermedi-ates and compounds. For more information please visit the company's websites at www.lonza.com or www.carnitine.com.